McGuire Michael K, Scheyer E Todd
Int J Periodontics Restorative Dent. 2006 Apr;26(2):127-33.
When mixed with an osteoconductive scaffold, recombinant human platelet-derived growth factor (rhPDGF-BB), a potent wound-healing protein, has been shown to promote clinical attachment gain, radiographic bone fill, and regeneration of the periodontium. This human case series evaluated the clinical outcome of rhPDGF with beta tricalcium phosphate (3-TCP) and a collagen membrane in the treatment of recession-type defects. The control was the clinical gold standard for root coverage: the subepithelial connective tissue graft (CTG). Seven patients with recession defects > or = 3 mm in contralateral quadrants of the maxilla, excluding molars, were treated in this series. Patients were followed postoperatively, and healing was evaluated at 8, 16, and 24 weeks, with recession depth as the primary outcome measure. This case series revealed a favorable tissue response to rhPDGF-BB + beta-TCP and a collagen membrane and comparable clinical outcomes to CTG, warranting a controlled clinical trial of greater magnitude.
当与骨传导支架混合时，重组人血小板衍生生长因子（rhPDGF-BB），一种有效的伤口愈合蛋白，已被证明可促进临床附着增加、影像学骨填充和牙周组织再生。该人类病例系列评估了rhPDGF与β-磷酸三钙（β-TCP）和胶原膜联合治疗退缩型缺损的临床效果。对照为根面覆盖的临床金标准：上皮下结缔组织移植（CTG）。本系列治疗了7例上颌对侧象限（不包括磨牙）退缩缺损≥3 mm的患者。术后对患者进行随访，并在8周、16周和24周时评估愈合情况，以退缩深度作为主要结局指标。该病例系列显示，rhPDGF-BB + β-TCP和胶原膜有良好的组织反应，且临床效果与CTG相当，因此有必要进行更大规模的对照临床试验。
